MENU
+Compare
IMDX
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$5.29
Change
+$0.68 (+14.72%)
Capitalization
151.54M

IMDX Insight Molecular Diagnostics Inc Forecast, Technical & Fundamental Analysis

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes... Show more

IMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMDX with price predictions
Oct 16, 2025

IMDX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for IMDX moved above the 200-day moving average on October 07, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 06, 2025. You may want to consider a long position or call options on IMDX as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMDX just turned positive on October 07, 2025. Looking at past instances where IMDX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 88 cases where IMDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMDX broke above its upper Bollinger Band on October 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IMDX's P/B Ratio (138.889) is very high in comparison to the industry average of (11.735). P/E Ratio (0.000) is within average values for comparable stocks, (139.668). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.780). IMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (27.624) is also within normal values, averaging (9.648).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
IMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RPMT0.36N/A
+0.64%
Rego Payment Architectures, Inc.
JCDXF18.50N/A
N/A
JC Decaux SA
NPACF15.57N/A
N/A
Quadient SA
KAOOY8.13-0.06
-0.73%
Kao Corp.
VRRCF0.02N/A
-13.51%
VR Resources Ltd.

IMDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then STRRP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMDX
1D Price
Change %
IMDX100%
+7.56%
STRRP - IMDX
37%
Loosely correlated
+0.03%
FATE - IMDX
31%
Poorly correlated
+0.65%
NEPH - IMDX
30%
Poorly correlated
-2.91%
GOSS - IMDX
29%
Poorly correlated
-4.15%
BMRN - IMDX
29%
Poorly correlated
-0.26%
More